{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T10:01:24Z","timestamp":1764324084222,"version":"3.46.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jiac.2025.102860","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T17:33:09Z","timestamp":1763746389000},"page":"102860","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Factors associated with TDF-to-TAF switching in chronic hepatitis B: A nationwide cohort study in South Korea"],"prefix":"10.1016","volume":"31","author":[{"given":"Hyemin","family":"Ha","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Il","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-5131","authenticated-orcid":false,"given":"Nam Kyung","family":"Je","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2025.102860_bib1","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2018.08.065","article-title":"Epidemiology and management of hepatocellular carcinoma","volume":"156","author":"Kulik","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jiac.2025.102860_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2003-37590","article-title":"Natural history and prognosis of hepatitis b","volume":"23","author":"Fattovich","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jiac.2025.102860_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000173419","article-title":"Epidemiology of hepatocellular carcinoma in Japan and Korea: a review","volume":"75","author":"Kim","year":"2008","journal-title":"Oncology"},{"key":"10.1016\/j.jiac.2025.102860_bib4","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","article-title":"Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission","volume":"5","author":"Sarin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2007.11.011","article-title":"Natural history of chronic hepatitis b: special emphasis on disease progression and prognostic factors","volume":"48","author":"Fattovich","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib6","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3904\/kjim.2016.180","article-title":"Risk of hepatitis b virus-related hepatocellular carcinoma development is much higher in Koreans than in Taiwanese fau - shim, jae-jun fau - Kim, jung wook fau - Kim, byung-ho","volume":"32","year":"2017","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.jiac.2025.102860_bib8","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000299","article-title":"Cost-effectiveness analysis of antiviral therapy for untreated minimally active chronic hepatitis b to prevent liver disease progression","volume":"12","author":"Lee","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jiac.2025.102860_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.lana.2024.100826","article-title":"Association of hepatitis b virus treatment with all-cause and liver-related mortality among individuals with hbv and cirrhosis: a population-based cohort study","volume":"36","author":"Makuza","year":"2024","journal-title":"The Lancet Regional Health \u2013 Americas"},{"key":"10.1016\/j.jiac.2025.102860_bib10","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1002\/hep.29321","article-title":"Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis b virus-endemic population","volume":"66","author":"Choi","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jiac.2025.102860_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-003265","article-title":"Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis b: systematic review and meta-analysis","volume":"3","author":"Thiele","year":"2013","journal-title":"BMJ Open"},{"key":"10.1016\/j.jiac.2025.102860_bib12","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12985-021-01589-x","article-title":"Functional cure for chronic hepatitis b: accessibility, durability, and prognosis","volume":"18","author":"Song","year":"2021","journal-title":"Virol J"},{"key":"10.1016\/j.jiac.2025.102860_bib13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1053\/j.gastro.2010.04.048","article-title":"Incidence and determinants of spontaneous hepatitis b surface antigen seroclearance: a community-based follow-up study","volume":"139","author":"Liu","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jiac.2025.102860_bib14","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP1497","article-title":"Hepatitis b surface antigen seroclearance during chronic hbv infection","volume":"15","author":"Chu","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jiac.2025.102860_bib15","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1093\/jac\/dku502","article-title":"Bone and kidney toxicity induced by nucleotide analogues in patients affected by hbv-related chronic hepatitis: a longitudinal study","volume":"70","author":"Maggi","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2025.102860_bib16","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3851\/IMP2649","article-title":"Tenofovir-associated Fanconi syndrome in patients with chronic hepatitis b monoinfection","volume":"18","author":"Gracey","year":"2013","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jiac.2025.102860_bib17","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/apt.13659","article-title":"Review article: long-term safety of nucleoside and nucleotide analogues in hbv-monoinfected patients","volume":"44","author":"Lampertico","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jiac.2025.102860_bib18","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jhep.2016.08.008","article-title":"Tenofovir disoproxil fumarate (tdf) vs. Emtricitabine (ftc)\/tdf in lamivudine resistant hepatitis b: a 5-year randomised study","volume":"66","author":"Fung","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib19","article-title":"The epidemiology of hepatitis b virus infection in Korea: 15-year analysis","volume":"39","author":"Kim","year":"2024","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.jiac.2025.102860_bib20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with hbeag-negative chronic hepatitis b virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96 weeks treatment of tenofovir alafenamide vs. Tenofovir disoproxil fumarate for hepatitis b virus infection","volume":"68","author":"Agarwal","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S2468-1253(24)00096-7","article-title":"Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis b and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study","volume":"9","author":"Janssen","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib23","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis b: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib24","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/jgh.16593","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis b","volume":"39","author":"Nam","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib25","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis b: aasld 2018 hepatitis b guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jiac.2025.102860_bib26","doi-asserted-by":"crossref","unstructured":"Cornberg M, Sandmann L, Jaroszewicz J, Kennedy P, Lampertico P, Lemoine M et al. Easl clinical practice guidelines on the management of hepatitis b virus infection. J Hepatol. doi 10.1016\/j.jhep.2025.03.018. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.018.","DOI":"10.1016\/j.jhep.2025.03.018"},{"key":"10.1016\/j.jiac.2025.102860_bib27","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3350\/cmh.2022.0084","article-title":"Kasl clinical practice guidelines for management of chronic hepatitis b","volume":"28","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.jiac.2025.102860_bib28","first-page":"743","article-title":"Drug-induced nephrotoxicity","volume":"78","author":"Naughton","year":"2008","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.jiac.2025.102860_bib29","first-page":"57","article-title":"Drug-induced renal disorders","volume":"4","author":"Ghane Shahrbaf","year":"2015","journal-title":"J Renal Inj Prev"},{"key":"10.1016\/j.jiac.2025.102860_bib30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.4065\/mcp.2010.0636","article-title":"Update on medications with adverse skeletal effects","volume":"86","author":"Davidge Pitts","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jiac.2025.102860_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.biopha.2007.04.008","article-title":"Tenofovir renal safety in hiv-infected patients: results from the scolta project","volume":"62","author":"Madeddu","year":"2008","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jiac.2025.102860_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cegh.2023.101462","article-title":"A review of tenofovir disoproxil fumarate associated nephrotoxicity among people living with hiv: burden, risk factors and solutions","volume":"25","author":"Asirvatham","year":"2024","journal-title":"Clinical Epidemiology and Global Health"},{"key":"10.1016\/j.jiac.2025.102860_bib33","article-title":"Gender differences in demographic and clinical characteristics in patients with hbv-related liver diseases in China","volume":"10","author":"Liu","year":"2022","journal-title":"PeerJ"},{"key":"10.1016\/j.jiac.2025.102860_bib34","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/ndt\/gfq656","article-title":"A population-based survey of chronic renal disease in turkey--the credit study","volume":"26","author":"S\u00fcleymanlar","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jiac.2025.102860_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.11005\/jbm.2020.27.4.281","article-title":"Osteoporosis and osteoporotic fracture fact sheet in Korea","volume":"27","author":"Ahn","year":"2020","journal-title":"J Bone Metab"},{"key":"10.1016\/j.jiac.2025.102860_bib36","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/ndt\/gft480","article-title":"Hypertension, glomerular hypertrophy and nephrosclerosis: the effect of race","volume":"29","author":"Hughson","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jiac.2025.102860_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000026276","article-title":"Determining the association between hypertension and bone metabolism markers in osteoporotic patients","volume":"100","author":"Hu","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.jiac.2025.102860_bib38","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.amjhyper.2004.08.016","article-title":"Hypertension as a risk factor for hip fracture","volume":"18","author":"P\u00e9rez-Castrill\u00f3n","year":"2005","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jiac.2025.102860_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-008-9198-2","article-title":"Hypertension is a risk factor for fractures","volume":"84","author":"Vestergaard","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jiac.2025.102860_bib40","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1478-3231.2004.00911.x","article-title":"Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study","volume":"24","author":"Huo","year":"2004","journal-title":"Liver Int"},{"key":"10.1016\/j.jiac.2025.102860_bib41","first-page":"2579","article-title":"Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma","volume":"7","author":"Zhou","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.jiac.2025.102860_bib42","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","article-title":"Vegf inhibition, hypertension, and renal toxicity","volume":"14","author":"Hayman","year":"2012","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.jiac.2025.102860_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1023660","article-title":"Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: a bayesian network meta-analysis","volume":"13","author":"Xiong","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jiac.2025.102860_bib44","first-page":"5","article-title":"Kdigo 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Eknoyan","year":"2013","journal-title":"Kidney Int"},{"key":"10.1016\/j.jiac.2025.102860_bib45","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.21873\/invivo.12843","article-title":"Antihypertensive drug combinations modify cisplatin-induced acute kidney injury","volume":"36","author":"Takeuchi","year":"2022","journal-title":"In Vivo"},{"key":"10.1016\/j.jiac.2025.102860_bib46","first-page":"197","article-title":"Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and nsaids: \u201cthe triple whammy\u201d","volume":"35","author":"Garcia","year":"2015","journal-title":"Nefrologia"},{"key":"10.1016\/j.jiac.2025.102860_bib47","article-title":"Incidence and factors associated with tenofovir-induced nephrotoxicity in hiv infected patients in nakornping hospital","volume":"11","author":"Suwan","year":"2020","journal-title":"J Nakornp Hospital"},{"key":"10.1016\/j.jiac.2025.102860_bib48","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1097\/QAD.0b013e3280b07b33","article-title":"The safety of tenofovir disoproxil fumarate for the treatment of hiv infection in adults: the first 4 years","volume":"21","author":"Nelson","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2025.102860_bib49","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3947\/ic.2023.0001","article-title":"Incidence and risk factors of tenofovir disoproxil fumarate induced nephrotoxicity and renal function recovery, a hospital case-control study","volume":"55","author":"Srisopa","year":"2023","journal-title":"Infect Chemother"},{"key":"10.1016\/j.jiac.2025.102860_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","article-title":"Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies","volume":"26","author":"Ungprasert","year":"2015","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jiac.2025.102860_bib51","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","article-title":"A meta-analysis of prior corticosteroid use and fracture risk","volume":"19","author":"Kanis","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jiac.2025.102860_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0330090","article-title":"Regional disparities in the distribution of public and private healthcare facilities in South Korea","volume":"20","author":"Park","year":"2025","journal-title":"PLoS One"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X25002570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:58:54Z","timestamp":1764323934000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X25002570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1341321X25002570"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102860","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with TDF-to-TAF switching in chronic hepatitis B: A nationwide cohort study in South Korea","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2025.102860","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102860"}}